Vaccine Development and Manufacturing

CPHI Award Granted to Evonik for Plant-based Adjuvant Used in Parenteral Drug Delivery

October 12, 2024

Evonik's plant-based squalene, PhytoSquene, used in parenteral drug delivery applications, won the CPHI Excellence in Pharma Award in the “Sustainability” category.

Key Takeaways from the Peer Exchange Discussion “Aligning mRNA Progress with Regulatory Streamlining”

October 02, 2024

There is potential to effectively marry the best aspects of mRNA as a modality, to other existing or nascent exciting platforms, such as gene editing.

EMA Recommends Mpox Vaccine for Adolescents

September 23, 2024

The agency is recommending the extension of the smallpox and mpox vaccine, Imvanex, to adolescents aged 12 to 17.

Responding to Mpox

September 03, 2024

A coordinated and international response is needed to help control the latest mpox outbreak in Africa.

Updated 2024–2025 mRNA COVID-19 Vaccines Approved and Granted EUA by FDA

August 22, 2024

The approvals and authorizations come amid a late summer surge in the virus that is tracking a bit earlier than the early fall wave in the US in 2023.

Experimental Malaria Vaccine Found Safe in Multiple Trials in Mali

August 18, 2024

National Institutes of Health’s National Institute of Allergy and Infectious Diseases collaborated with the University of Sciences, Techniques and Technologies of Bamako, Mali to conduct the trials.

Positive Results for RSV Vaccine in Substudy of Phase III Trial of Immunocompromised Patients

August 12, 2024

The virus, which is contagious and a common cause of respiratory illness, hospitalizes up to 160,000 people and is responsible for as many as 13,000 deaths in the United States every year.

GSK and CureVac Enter into Licensing Agreement

July 04, 2024

The companies have restructured their existing collaboration into a licensing agreement that invests in mRNA development.

WACKER and CordenPharma Consortium Enters Pandemic Readiness

June 19, 2024

The companies have completed the expansion and qualification phase and now enter a stand-by phase for five years.

Clone Track Underpinning Study for Personalized Pancreatic Cancer mRNA Vaccine (ASGCT 2024)

May 24, 2024

An ASGCT Panel titled Novel Nucleic Acid and Cell-based Vaccines for Cancer highlights promising mRNA personalized cancer vaccine work.